Modification of the Lung Transplant Recipient Follow-up Form (TRF) to Better Characterize Longitudinal Change in Lung Function following Transplantation

OPTN/UNOS Thoracic Organ Transplantation Committee

Prepared by: Kimberly Uccellini, MS, MPH
UNOS Policy Department

Contents

Executive Summary 1
What problem will this proposal address? 2
Why should you support this proposal? 3
   How was this proposal developed? 3
   How well does this proposal address the problem statement? 11
Was this proposal changed in response to public comment? 12
Which populations are impacted by this proposal? 14
How does this proposal impact the OPTN Strategic Plan? 14
How will the OPTN implement this proposal? 14
How will members implement this proposal? 15
   Transplant Hospitals 15
   Will this proposal require members to submit additional data? 15
How will members be evaluated for compliance with this proposal? 15
How will the sponsoring Committee evaluate whether this proposal was successful post implementation? 15
Modification of the Lung Transplant Recipient Follow-up Form (TRF) to Better Characterize Longitudinal Change in Lung Function following Transplantation

Affected Policies: N/A
Sponsoring Committee: Thoracic Organ Transplantation Committee
Public Comment Period: January 22, 2018 – March 23, 2018
Board of Director’s Date: June 11-12, 2018

Executive Summary

The current OPTN/UNOS adult and pediatric lung and heart-lung Transplant Recipient Follow-up form (TRF) collects lung graft function status limited to bronchiolitis obliterans syndrome (BOS). The Thoracic Organ Transplantation Committee (Committee) identified two issues with the way graft function data is collected on the TRF, which limits the utility of this data in the context of chronic lung rejection:

- BOS data collection is outdated, incomplete, and inaccurate
- Restrictive allograft syndrome (RAS) is not collected at all

The limited data currently collected does not capture accurate information of all the prognostic possibilities for declining graft function and may not accurately describe the type of rejection a patient is exhibiting. Chronic lung allograft dysfunction (CLAD) is a broader, more contemporary definition of post-transplant lung dysfunction, encompassing both obstructive and restrictive chronic lung rejection. This proposal will modify the adult and pediatric lung and heart-lung TRFs to provide accurate longitudinal change in lung physiology after lung transplantation. This information can be utilized to evaluate CLAD in the US lung transplant population and will align with updated professional definitions. Refining the outcomes data the OPTN collects can better inform future policy.

This proposal aligns with the OPTN strategic goal of improving transplant recipient outcomes by collecting more granular data on lung dysfunction to help inform future policies for improving lung transplant outcomes. In addition, it will more accurately characterize longitudinal change in lung function following transplantation. Finally, examining outcomes other than strictly survival (in particular, quality-of-life measures such as pulmonary function) will be important for patient and program assessment.

What problem will this proposal address?

The current OPTN/UNOS adult and pediatric lung and heart-lung Transplant Recipient Follow-up form (TRF) collects lung graft function status limited to bronchiolitis obliterans syndrome (BOS). The Committee identified two issues with the way graft function data is collected on the TRF, which limits the utility of this data in the context of chronic lung dysfunction:

- BOS data collection is outdated, incomplete, and inaccurate
- Restrictive allograft syndrome (RAS) is not collected at all

BOS data collection is outdated, incomplete, and inaccurate

CLAD is a broader, more contemporary definition of post-transplant lung dysfunction, encompassing both obstructive and restrictive chronic lung rejection. Restrictive allograft syndrome (RAS) is a recently described phenotype of CLAD that represents restrictive physiologic change rather than the progressive obstructive physiologic change seen in BOS. The Committee is concerned that programs may be misclassifying RAS patients as having BOS based on the current TRF. The lung transplant community recognizes this new phenotype of chronic lung rejection and has asked UNOS how to report RAS or CLAD generally. Another issue is that BOS reporting is subject to error since reported information is not a reliably measured parameter and may not be readily available for data entry by personnel. The OPTN simply collects the patient’s BOS grade diagnosed by the clinician and the forced expiratory volume in one second (FEV1) as reported by the transplant program. The TRF does not collect other additional objective clinical parameters that support a diagnosis of BOS. There also may be some subjectivity in the way the data is collected. Finally, the TIEDI form is not programmed to calculate the presence of BOS or BOS stage since all relevant clinical parameters are not reported.

Restrictive allograft syndrome (RAS) is not collected

The Committee also recognized that the TRF does not collect information on RAS. This leads to two additional problems: 1) the number and types of outcomes for patients diagnosed with RAS is unknown; and 2) transplant programs have no clear way to report RAS.

1. The number of and outcomes for patients diagnosed with RAS is unknown

Because it is a new phenotype of chronic lung rejection and is not reported to the OPTN, there is no data repository for this information. Reporting objective measures that can predict RAS will help inform future policy, as well as help the lung transplant community better understand long-term lung transplant outcomes. It may also be useful in managing RAS.

2. Transplant programs have no clear way to report RAS

The TRF does not currently collect RAS, and there is no way for transplant programs to report it. The only option if a patient is experiencing RAS is to report “No BOS,” which is not inaccurate, but vague. The program could select “Unknown,” which is not accurate if a patient is diagnosed with RAS. This situation has prompted programs to contact UNOS and question how RAS should be reported. This could lead to variation in how chronic lung rejection is currently being reported.

Consequently, the limited data currently collected does not capture all the possibilities for declining graft function and may not accurately describe the type of rejection a patient is exhibiting. CLAD is a broader, more contemporary definition of post-transplant lung dysfunction, encompassing both obstructive and

---


restrictive chronic lung rejection. This proposal will modify the adult and pediatric lung and heart-lung TRFs to align with updated professional definitions. In addition, refining the outcomes data the OPTN collects will better inform future policy.

Why should you support this proposal?

This proposal will modify the data elements captured within the graft function section of the TRF. The elements selected are objective and standardized. They are easily accessible within a patient’s medical record for both clinical and non-clinical coordinators and require no interpretation. This format should improve the accuracy and completeness of reporting. In addition, the modifications to the TRF will allow for the collection of information to identify any new phenotype of chronic lung dysfunction. This information may inform new policy or strategies that may serve to improve long-term survival after lung transplantation. Finally, this data collection effort is informed and justified by the OPTN Principles of Data Collection, which state that “institutional members must provide sufficient data to the OPTN to allow it to: a) Develop transplant, donation and allocation policies;... c) determine member-specific performance.”

How was this proposal developed?

UNOS has received questions about how to report CLAD and RAS from several transplant programs, which prompted the Committee to discuss this issue. The Lung Committee (Committee) was supportive of pursuing it because improving outcomes for lung transplant recipients is a priority in the lung transplant community. Finally, collecting better data can better inform future policy.

The Committee discussed potential barriers to pursuing this project. Data collection projects are scrutinized to ensure they align with the OPTN Principles of Data Collection and there is sound justification to imposing additional administrative burden on members. Additional data reporting can be burdensome to members if data is difficult to obtain or if the data elements require some level of interpretation by a coordinator. In addition, members are sensitive to the amount of time coordinators spend on data entry. Another concern the Committee anticipated was whether the data could be found elsewhere (e.g. in literature). However, the CLAD nomenclature is relatively recent so information is somewhat limited. Finally, the Committee discussed potentially expanding the project scope to include evaluating and potentially changing the acute lung rejection fields on the TRF. These fields can be as vague and incomplete as the chronic lung rejection data fields. If the scope of the project expanded, this project may have taken longer than anticipated to complete. The programming cost was already projected to be significant, so cost/benefit was considered. The Committee ultimately decided to prioritize changing the acute rejection fields with other Committee project ideas at a later time.

The Committee collaborated with the Scientific Registry of Transplant Recipients (SRTR) and the OPTN/UNOS Data Advisory Committee (DAC) during the development of the proposed data fields. The SRTR provided insight into how data could be used for outcomes research, in addition to the aforementioned goals of the project. The Committee sought the DAC’s input about the data elements proposed and it endorsed the Committee’s due diligence in vetting those elements against the OPTN’s Principles of Data Collection.

The Committee considered multiple data elements on the current TRFs as it developed this proposal, and ultimately proposed the following changes to the TRF:

- Modify current FEV1 field and add Forced Vital Capacity (FVC) and Forced Expiratory Flow 25–75% (FEF 25–75) fields
  - All elements collected at three time intervals on each TRF
- Modify Bronchial Stricture and Oxygen Requirement fields

---

8 Organ Procurement and Transplant Network. Principles of Data Collection.
Modify current FEV1 field and Add Forced Vital Capacity (FVC) and Forced Expiratory Flow 25–75% (FEF 25–75) Fields

The Committee began by reviewing the current TRF (Figure 1).

![Figure 1: Adult Lung Transplant Recipient Follow-up Form (TRF)](image)

Committee members discussed whether it would be sufficient to collect very general information, similar to how BOS is currently collected, or whether there is more value in collecting more granular data. While simply asking whether the patient has CLAD and then selecting “BOS” or “RAS” could be adequate, collecting high-level information is vulnerable to the same subjectivity issues as the current BOS is currently collection. The data may end up being too broad to be useful for future policy development. Some members favored more specific data elements, and perhaps even programming UNetSM to calculate BOS (or RAS). This would enable the OPTN to better monitor changes over time, especially if the condition was calculated rather than reported by a data coordinator. Committee members acknowledged that increased data collection and reporting may not be well received by the community, but if the community believes in the value of having this information that might mitigate concerns over the administrative burden.

Due to the problems associated with collecting high level BOS and RAS data, the Committee reached consensus to instead select objective measures relevant to CLAD. They considered the following:

- Forced expiratory volume in one second (FEV1)
- Forced vital capacity (FVC)
- FEV1/FVC ratio
- Absolute FVC and FEV1
- Total lung capacity
- Lung volumes
- BOS

There was early consensus to keep the FEV1 field on the TRF as it is a standard spirometry measurement used in diagnosing and calibrating the severity of chronic lung disease. Likewise, there was agreement to add FVC. Committee members generally agreed that most centers do not collect total lung capacity data on a regular basis; rather, this data is collected only if there is a specific issue. In addition, programs tend not to collect this data because of the high volume of patients, which makes it difficult to get pulmonary function tests (PFTs) done in clinic. As a result, including a total lung capacity field might
The members agreed that the FEV1/FVC ratio doesn't need to be requested since it can be calculated based on provided information, so Committee opted to add forced expiratory flow during middle one half of the FVC (FEF25-75) versus FEV1/FVC ratio. Likewise, the Committee discussed whether to gather data for percent predicted for FEV1, but agreed not to because percent predicted can be calculated using other primary data already collected on the forms, such as height, race, date of birth, and gender. The Committee felt that requesting data for percent predicted would be redundant as well as add unnecessary work for those filling out the forms. Participants debated the relevance of confounding conditions that may affect proposed data points in establishing a CLAD diagnosis, including reflux/fundoplication surgery, airway stenosis, and the presence of an infection on the date of PFT collection. The Committee agreed that information about fundoplication surgery likely doesn't need to be collected. The Committee also agreed that both airway stenosis and infection represent reversible conditions whereas CLAD is a progressive syndrome. The Committee settled on collecting FVC, FEV1, and the FEF25-75. These three data points would also enable the detection of patients who develop obstructive versus restrictive CLAD.3

Once the Committee settled on those data elements, it focused on analyzing the BOS data field. During deliberations, the Committee posited that the Yes/No variable for BOS scoring is likely correct, but the grading may need adjusting to attain more consistent reporting among centers. The Committee was in agreement that any data that needs interpretation before being captured is less reliable. To determine who has BOS with some degree of confidence, data needs to be objective rather than subjective. Therefore, it was suggested that rather than asking for a BOS diagnosis on the forms, a better approach might be to ask for raw numbers at certain timeframes. UNet could then calculate when patients meet BOS criteria. By taking the subjectivity out of data collection, this approach would make it easier for nonclinical staff, such as data coordinators, to enter information accurately. It would also make data reporting more efficient. Finally, this approach could also use the raw data collected to refine definitions of both RAS and BOS.

The Committee discussed possible reasons for inconsistency in data reporting, such as:

- Transplant program staff may be utilizing different definitions of BOS
- Non-clinical coordinators do not understand the meaning of BOS
- It can be difficult even for experts to classify people correctly due to symptoms
- Definitions of disorders change over time; BOS itself used to be considered an irreversible airway disease
- There might be logistical issues contributing to the inaccuracy, such as difficulty in locating pertinent information in patient charts

The group quickly came to consensus that this field may be prone to subjectivity based on the way it is being asked, and agreed to evaluate further.

To determine the accuracy and completeness of data currently collected on the TRF, the Committee requested data showing the distribution of responses to the BOS field on the TRF generated and validated 1-5 years post-transplant, by form anniversary type (1 year – 5 year, Death, and Graft Failure forms). In addition, Committee members requested the number of lung transplant recipients that progressed to higher BOS stages as represented through the follow-up reporting and the types of progressions that were reported. Table 1 provides a summary of the number of increases reported in BOS status by maximal BOS stage status reported for adult lung alone transplant recipients from 2009 through 2015. Table 2 summarizes the number of decreases reported in BOS status by max status reported for the same cohort.
Table 1: Number of Increases Reported in BOS Status by Max Status Reported

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade OP or UNK</td>
<td>391</td>
<td>1366</td>
<td>52</td>
<td>0</td>
<td>1809</td>
</tr>
<tr>
<td>Grade 1</td>
<td>105</td>
<td>407</td>
<td>100</td>
<td>7</td>
<td>619</td>
</tr>
<tr>
<td>Grade 2</td>
<td>53</td>
<td>206</td>
<td>110</td>
<td>8</td>
<td>377</td>
</tr>
<tr>
<td>Grade 3</td>
<td>116</td>
<td>493</td>
<td>245</td>
<td>19</td>
<td>873</td>
</tr>
<tr>
<td>Total</td>
<td>665</td>
<td>2472</td>
<td>507</td>
<td>34</td>
<td>3678</td>
</tr>
</tbody>
</table>

Table 2: Number of Decreases Reported in BOS Status by Max Status Reported

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade OP or UNK</td>
<td>1146</td>
<td>647</td>
<td>16</td>
<td>1809</td>
</tr>
<tr>
<td>Grade 1</td>
<td>338</td>
<td>255</td>
<td>26</td>
<td>619</td>
</tr>
<tr>
<td>Grade 2</td>
<td>246</td>
<td>113</td>
<td>18</td>
<td>377</td>
</tr>
<tr>
<td>Grade 3</td>
<td>674</td>
<td>181</td>
<td>18</td>
<td>873</td>
</tr>
<tr>
<td>Total</td>
<td>2404</td>
<td>1196</td>
<td>78</td>
<td>3678</td>
</tr>
</tbody>
</table>

To help visualize the trends observed in BOS reporting, Figure 2 shows twelve examples of BOS reporting trajectories for randomly selected individuals with follow-up including a max BOS reported as Grade 3 and at least two sequential increases and no decreases reported. This example represents the types of BOS follow-up that would be expected as the data is currently collected for a progressive disease.

Figure 2: Randomly Selected Individuals with a Max BOS Reported as Grade 3 and at Least Two Sequential Increases and No Decreases
However, Figure 3 shows twelve more examples of BOS reporting trajectories for randomly selected individuals with follow-up including a max BOS reported as at least Grade 2 and at least two decreases in BOS reported through follow-up.

**Figure 3: Randomly Selected Individuals with a Max BOS reported as at Least Grade 2 and at Least Two Decreases Reported to Depict the Variation in BOS Reporting**

This data illustrates the inconsistency in data reporting for BOS on the current TRF. The evidence shown in the analysis supports the claim that the current subjective criteria that is collected on the TRF using the BOS field does not always adequately represent the staging of chronic rejection in lung transplants. Trends shown in this report indicate that transplant programs likely do not see the progression through BOS stages the same way, and the data is not collected consistently within each program or patient year to year. The Committee felt this evidence supports efforts for more precise data collection focused on objective data fields, including FEV1 and FVC.

Ultimately, the Committee agreed on collecting FEV1, FVC, and FEF25-75 on each TRF in place of the current BOS field.

**Modify Bronchial Stricture and Oxygen Requirement Fields**

The Committee evaluated whether to keep the other remaining two questions from the Graft Function section of the TRF:

- “Bronchial Stricture (since last follow-up)”
  - “If yes, stent?”
- “O2 Requirement at Rest”

Committee members asked whether members were currently reporting this data, as at least one member indicated the O2 requirement at rest wasn’t being utilized. The Committee discussed whether to modify or remove the “bronchial stricture” and the oxygen at rest questions. While these data elements don’t directly contribute to the lung allocation score (LAS), they can help identify risk factors that do inform the LAS. They advocated eliminating it if the data is not purposeful. SRTR shared that it does not use it in the annual data report, but thought that investigators do use it in survival analyses. The Committee
requested information on complete data reporting for bronchial stricture and oxygen requirement at rest on the TRFs to aid in the discussion of the project.

For bronchial stricture reporting, Table 3 demonstrates a gradual increase in missing values and therefore a decrease in reported values across the year 1-5 TRFs.

<table>
<thead>
<tr>
<th>Form</th>
<th>Missing (%)</th>
<th>Recorded Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year</td>
<td>1.4</td>
<td>98.6</td>
</tr>
<tr>
<td>2-year</td>
<td>1.6</td>
<td>98.4</td>
</tr>
<tr>
<td>3-year</td>
<td>2.6</td>
<td>97.4</td>
</tr>
<tr>
<td>4-year</td>
<td>4.1</td>
<td>95.9</td>
</tr>
<tr>
<td>5-year</td>
<td>5.0</td>
<td>95.0</td>
</tr>
<tr>
<td>Death</td>
<td>16.7</td>
<td>83.3</td>
</tr>
<tr>
<td>Graft failure</td>
<td>12.2</td>
<td>87.8</td>
</tr>
</tbody>
</table>

A majority of responses for this question were “no,” with a higher percentage of affirmative responses reported on the 1-year TRF and a decreasing trend over time. Bronchial stricture reporting dropped noticeably at the time of reporting death or graft failure. For O2 requirement at rest, Table 4 shows that within 5-years of transplant for all adult lung alone transplants 2009-2015, approximately 20% of values were missing.

<table>
<thead>
<tr>
<th>Form</th>
<th>Missing (%)</th>
<th>Recorded Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year</td>
<td>18.3</td>
<td>81.7</td>
</tr>
<tr>
<td>2-year</td>
<td>18.6</td>
<td>81.4</td>
</tr>
<tr>
<td>3-year</td>
<td>19.4</td>
<td>80.6</td>
</tr>
<tr>
<td>4-year</td>
<td>18.9</td>
<td>81.1</td>
</tr>
<tr>
<td>5-year</td>
<td>19.4</td>
<td>80.6</td>
</tr>
<tr>
<td>Death</td>
<td>41.1</td>
<td>58.9</td>
</tr>
<tr>
<td>Graft failure</td>
<td>22.1</td>
<td>77.9</td>
</tr>
</tbody>
</table>

The Committee also viewed variation in reporting oxygen requirement at rest. Data indicated a majority of programs complete this field, and only an outlying minority account for 20% of the missing data.

The Committee discussed the possible implications of the data reported on the collection of bronchial stricture and oxygen requirements.

1. Bronchial Stricture

The Committee acknowledged that the response options for “bronchial stricture” (“yes,” “no,” or “unknown”) were not entirely useful, and may not be the best choices for this condition. Since strictures typically occur early post-transplant, it may only be logical to retain the question on the 6-month and 1 year TRF. The data presented supports this idea. UNOS staff encouraged the Committee to keep the 1-5 year TRF standardized to the extent possible.

There was some debate on whether to only capture stenosis on the 6-month form, not capture it at all, or capture it for a limited time beyond 6-months (1 or 2 years). When evaluating for chronic lung rejection, ruling out presence of bronchial stricture is required. One member mentioned that ISHLT might be examining stenosis more critically to better define and report it. The group acknowledged that multiple factors could impact strictures, such as the surgery itself, ex vivo lung perfusion (EVLP), or recipient factors. While it may not impact survival, it does interplay with quality of life and lung function. The Committee agreed that the way the bronchial stricture questions were asked likely contributed to the inability to interpret the data and the question in its current form should be eliminated. However, the Committee could not come to consensus on how to reword the question, so it instead proposed retaining the field, but asking the community for feedback about how to word this question during public comment.
After public comment, the Committee decided to eliminate this field. The Committee’s discussions surrounding this issue are summarized below in the “Was this proposal changed after public comment?” section, below.

2. Oxygen Requirement at Rest

The Committee was interested in data for oxygen requirement at rest. There was consensus that this variable is important, as supplemental oxygen need may be used in survival analyses and should be retained. For example, oxygen requirement may be indicative of medical urgency: one member gave the example of a patient who did not need oxygen at rest, but did with exertion. The Committee believed the question needed to be modified to elicit more meaningful information. One member suggested that the “at rest” information may be subjective, since it may be self-reported, the actual need at the time of the clinic visit, what is prescribed, or what is required on a six minute walk test. One member suggested mirroring how the question is asked upon registration by eliciting what the oxygen requirement is at rest and with exercise. Several members commented that additional clarification would be helpful to coordinators (e.g. room air = 0 L/min). There was consensus to keep the oxygen at rest field because it is important for survival analysis, but the Committee agreed to add additional fields under oxygen requirement: at rest and with exercise.

Reporting Baseline, “Best,” and “Worst” Measures

During proposal development, the Committee discussed additional ways to utilize PFT data. One idea was to have UNet calculate whether the values indicated BOS or RAS from baseline PFT results which would consist of two highest values for FEV1, FVC and FEF25-75, collected at least three weeks apart. These values would then carry forward to subsequent TRFs. Members wanted these fields to be editable, so they could be updated if the patient had higher values in year two (versus year one). Members proposed another field to collect the most recent PFT values, closest to the patient's anniversary. In subsequent years, these fields (baseline + most recent values) would pop up and ask whether the patient's highest PFTs have changed or not.

The Committee also revisited a previous decision regarding having more recent spirometric values replace the initially reported baseline values if they are greater. On the 6-month TRF, programs would report the two highest values of FEV1, FVC and FEF25-75, collected at least three weeks apart post-transplant regardless of test date. These will be considered the baseline values. On subsequent forms, the two highest values previously reported would carry over, and programs would report the “most recent” data for FEV1, FVC and FEF25-75. If more recent spirometric values were greater than the previous highest baseline values, the new value would adjust to become the new baseline.

There was some consensus that operationalizing this decision was making programming too complicated and could potentially impact the accuracy of the data.

From a programming and data analysis perspective, the Committee discussed recommendations to keep functionality simple and only collect the data, rather than programming UNet to perform any type of analyses based on these data elements. Only including the “best” PFT values runs the risk of skewing the data so outcomes look better than they are early on post-transplant and perhaps worse later. Including only the “worst” PFTs would be subject to the same bias. If data is collected in an organized way with well-defined data points at well-defined intervals, the overall behavior of the group will be detected in a large cohort. Choosing the “best” or “worst” PFTs would dilute the value of the data especially in a case like CLAD where definitions are evolving.

The Committee agreed that reporting “best” or “worst” values may introduce additional administrative burden for coordinators and may bias results. One Committee member asked whether reporting values from an internal transplant center lab versus an outside lab would lead to variability. Other members noted spirometry testing was reproducible and standardized so that might not be an issue. A potential solution to mitigate this concern is to limit reporting PFT values to those collected by the transplant center.

After these discussions, the Committee agreed not to have UNet calculate BOS or RAS in the background. Calculations of BOS or RAS from the raw data could be part of the post-implementation evaluation, but this functionality will not be part of the TRF.
The Committee also agreed that although they were abandoning reporting “best” and “worst” measures; they did feel collecting data over time would be informative.

**Time Intervals**

The Committee proposed collecting dates for these values, although this is not current practice on TIEDI forms. Dates are informative by providing information on time to peak spirometric values, or may identify how many recipients have their best lung function several years after transplantation. If dates are not collected, more assumptions may have to be made (e.g. on an annual form, an assumption might be that the values were obtained on the date of form submission). Collecting dates could provide more granularity, accuracy, and consistency. From an outcomes perspective, the Committee may be interested in the rate of decline in FEV1 as a predictor of death; if so, it is best to collect dates.

A member suggested adding an extra standardized point in time during which programs report data; this would standardize reporting and add additional data points to analyze. For example, on the one-year TRF, programs would report values at 9 and 12 months; on the 2-year TRF, they would report values from 18 and 24 months, etc. Dates would still be captured. This would also address the Committee’s concerns regarding collecting very limited data (annual reporting).

As a result of these considerations, the Committee debated including two, three, or four time intervals on each form. Committee members were sensitive in attempting to balance the administrative burden of reporting PFT values at multiple time intervals with getting useful data. One suggestion was to collect more data immediately post-transplant (1- and 2-year TRF) as that is when patients experience the most variability in lung function. Members acknowledged this made sense as most patients perform frequent testing in the first year, with a decreased frequency over time if the patient is stable. However, if a clinician detects a change or decline in lung function, testing will increase. In addition, early changes (<1 year) in lung function are not likely to be associated with CLAD.

The Committee determined that since the TRF is a government-approved form, it is best practice to keep the data fields as standardized as possible. In light of these limitations, there was broad consensus to include at least two time intervals on each form. Coordinators are likely to support reporting of simple raw data rather than an interpretation or attempting to list the “best” values. The Committee ultimately compromised on three time intervals. The group acknowledged that the further out from transplant the patient is, the more likely the transplant program may not be able to report three data points. The Committee was okay with this as long as at least two values were reported. The group agreed to include three time intervals on the 6-month TRF, the 1-5 year TRF, and the 6+ year TRFs. There was strong consensus to include a detailed explanation of the time intervals, and labels should be standardized across the forms.

**Data Element Standards of Review**

The Committee consulted the Data Advisory Committee’s (DAC) Data Element Standards of Review to ensure that a strong case could be made to request modification to the TRF fields.
### Figure 6: Data Element Standards of Review Analysis

<table>
<thead>
<tr>
<th>Component or Measure</th>
<th>Criteria &amp; Response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OPTN Data Collection Principles</strong></td>
<td><em>Is the proposal for collection of this element consistent with at least one of the principles?</em> Yes, the Committee confirmed the purpose for collecting new data elements is to inform future policy.</td>
</tr>
<tr>
<td><strong>Purpose, Population and Outcomes</strong></td>
<td><em>Have the purpose, population, and intended outcomes of collecting this element been clearly articulated?</em> The Committee vetted the problem, impacted population, and intended outcomes of collecting new data at a previous meeting. Committee members agreed that the data is being collected in a way that isn't interpretable, so the goal is to optimize the data that is already being collected.</td>
</tr>
<tr>
<td><strong>Definition and Reliability</strong></td>
<td><em>Is the data element definition sufficiently clear to enable consistent entry? Is the element and collection mechanism designed to consistently reproduce the same results? Are there variations in interpretation that would reduce the utility?</em> The proposed elements are objective and consistent across all programs, thus minimizing confusion.</td>
</tr>
<tr>
<td><strong>Face Validity</strong></td>
<td><em>Is the element capable of eliciting the data we seek? Is the data a proxy for the concept you’re trying to measure?</em> The proposed data elements are included in the definition of CLAD.</td>
</tr>
<tr>
<td><strong>Availability</strong></td>
<td><em>Is this element widely available for the population of patients for which it is sought to be collected?</em> All of the proposed elements are consistently collected and reported by transplant centers.</td>
</tr>
<tr>
<td><strong>Alternative Data Sources</strong></td>
<td><em>Have alternatives to collecting this by the OPTN been explored? Is this element already available via an external source? There are no alternatives to collecting it directly from the patient population.</em></td>
</tr>
</tbody>
</table>

In addition, the Committee consulted with the OPTN/UNOS Data Advisory Committee for input. As a result of DAC’s review, there was no substantive feedback on necessary changes. DAC members found the proposal to be thoroughly vetted with well-selected data fields that could inform future policy. However, the DAC did note that the status (ST) drop-down field, which permits a program to enter “unknown,” could lead to unclear data. The DAC did acknowledge that this field is used across all forms and organ-types, thus modifying it should be part of a larger effort.

The Committee voted unanimously to approve the proposal for public comment in spring 2018 (13 Approve, 0 Oppose, 0 Abstentions).

**How well does this proposal address the problem statement?**

This proposal makes better use of the lung graft function data fields by utilizing data already available through PFTs. By modifying existing fields and adding FVC and FEF25-75, the data will better characterize longitudinal changes in lung function following transplantation.
Was this proposal changed in response to public comment?

The response to the proposal was generally favorable, with various recommendations suggested. Overall, all eleven OPTN regions approved with no changes via the consent agenda. Professional societies offered more substantive feedback, but generally approved of the Committee’s recommendations. One pulmonologist commented on the proposal:

The proposal garnered a total of 6 comments. The Committee requested specific feedback from the community regarding whether to keep the bronchial stricture/stent question on the 6-month and 1-5 year TRFs. If commenters favored keeping the question, the Committee hoped for input on how the question could be better asked to elicit more meaningful data regarding this short-term complication. The Committee also sought feedback on whether the number of time intervals proposed for FEV1, FVC, and FEF25-75 was reasonable. Consequently, this feedback, among other comments, is reflected in the following overarching themes, detailed below. The Committee’s response and any subsequent changes made post-public comment are elaborated upon within each theme.

- Additional data elements/testing
- Bronchial stricture
- Administrative concerns

Additional data elements/testing methodologies

Two societies, AST and ISHLT, suggested additional data elements obtained by testing methodology beyond spirometry. AST recommended the Committee consider other ways to add phenotypic specificity to the evaluation of chronic rejection: the phenomenon of “azithromycin responsive” CLAD (or NRAD, neutrophilic reversible allograft dysfunction) has likewise been accepted in clinical practice for years without incorporation into the contemporary data collection paradigm. In addition, it advised considering future incorporation of plethysmography into this data collection: the lung transplant community has not definitively established that spirometry is sufficient, in all cases, to distinguish RAS. Being able to make the diagnosis of RAS without plethysmography at every visit represents an important advance in the field; nevertheless, it would be reasonable to anticipate that a center should want total lung capacity data at the time that an RAS diagnosis is being made. Similarly, ISHLT noted that definitions of RAS used in the
literature have frequently required imaging and/or clinical data in addition to spirometric data, but acknowledged collecting this information may be difficult. Therefore, it expressed concern about the feasibility of collecting the necessary data to refine the OPTN database on chronic lung allograft dysfunction.

The Committee considered the feedback regarding additional methodologies. Members noted that during the development of the proposal, only one Committee member confirmed their program did annual plethysmography testing to obtain total lung capacity. There was agreement to exclude this suggestion because this test is not standard practice; in addition, one member noted that insurance coverage for this testing may not allow reimbursement. There was consensus that the addition of this test would more likely lead to missing data and maybe too substantive a change. Likewise, the Committee determined not to add additional variables to garner phenotypic specificity since these elements are not objective or standardized and require interpretation. Further, members noted that the goal of the proposal was not to define RAS or CLAD, but to longitudinally record post-transplant pulmonary physiologic change that will allow a more accurate evaluation of CLAD. Challenges in the recording and standardization of image interpretation prohibits the addition of this particular parameter. Therefore, the Committee was comfortable not including additional data elements.

Bronchial stricture

The Committee considered feedback regarding the bronchial stricture field. This complication typically arises within the first year post-transplant and is multi-factorial: surgical, infectious, and ischemia, among other factors.

Only two societies provided feedback, and they were antithetical. ASTS advised removing the question altogether. ISHLT recommended keeping it on the 6-month and 1-year TRF. The former shared concerns regarding the reliability of the data. In addition, no one could think of a better way to ask the question to elicit better information. Another member offered that ISHLT might have recommended keeping the question based on recently completed airway guidelines. Members asked if consulting the new ISHLT guideline could be informative to the discussion. One member commented the guidelines define “stricture”, provide a grading system, cover incidence and highlight treatments, so there was uncertainty how relevant the guidelines would be. Members emphasized that bronchial stricture should be ruled out prior to diagnosing CLAD. Keeping it may only be informative if the Committee and community were interested in the prevalence of stenosis, especially if this data is not collected elsewhere. However, the Committee acknowledged this rationale does not completely align with the OPTN Principles of Data Collection. Post-public comment, the Lung Committee recommended keeping the question on the 6-month and 1-5 year TRF, but clarifying the question. Suggestions included asking whether the stenosis required dilation or stent placement, and has the recipient had a stricture since the last TRF.

The Committee discussed the Lung Subcommittee’s recommendations. Practically, a program is unlikely to be able to determine, long-term, whether a recipient had a bronchial stricture due to it being a short-term complication. Even if the question was reworded, the Committee was skeptical whether the information would be accurate after a certain period of time, or ultimately useful. Therefore, the Committee decided to remove the question completely from all forms.

Administrative burden

Public comment indicated concern around administrative burden. Data entered by a non-clinician versus a clinical coordinator could be an issue. One commenter opined that data entry (i.e., presence/absence of CLAD, BOS, RAS) should be performed using a consistent protocol, especially given that there is some subjectivity to the diagnoses, and some programs’ data entry personnel may not have sufficient training to delineate CLAD subtype. Likewise, there was a comment expressing concern regarding significant variability in the interpretation and collection of these data elements by clinical coordinators across different centers and within the same center. However, the Committee felt these were theoretical

---

concerns as the Committee deliberately selected objective data points that do not require any interpretation and are easily accessible in the medical record. In addition, the lung transplant coordinator on the Committee confirmed that the burden should in fact be equal or even less than it is currently, as coordinators will not have to comb the medical record for a statement of BOS or make an interpretation whether the patient has BOS. Therefore, no changes were made.

Additional feedback

The Committee posed a question to the community about whether the number of time intervals proposed (3) was reasonable. AST submitted the only response to this question indicating it concurred with the suggestion. The Committee opted to keep three time intervals.

Finally, ISHLT pointed out that there is currently no widely accepted definition for Restrictive Allograft Syndrome (RAS). The Committee acknowledged these concerns but reaffirmed the intent was not to define a CLAD phenotype, but to collect the most objective, readily available, easily identifiable, reproducible variables.

Ultimately, the Committee voted to send the proposed data elements unchanged to the Board of Directors in June for consideration, with the exception of removing the bronchial stricture and companion stent question from all forms (14-approve, 0-oppose, 2-abstentions).

Which populations are impacted by this proposal?

This proposal impacts information collected for all recipients post lung or heart-lung transplant. Table 7 shows the number of lung and heart-lung transplants performed in 2017:

<table>
<thead>
<tr>
<th>Age</th>
<th>Lung</th>
<th>Heart-Lung</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 18 Years</td>
<td>44</td>
<td>1</td>
<td>45</td>
</tr>
<tr>
<td>18 + Years</td>
<td>2405</td>
<td>28</td>
<td>2433</td>
</tr>
<tr>
<td>Total</td>
<td>2449</td>
<td>29</td>
<td>2478</td>
</tr>
</tbody>
</table>

How does this proposal impact the OPTN Strategic Plan?

1) **Increase the number of transplants:** There is no impact to this goal.

2) **Improve equity in access to transplants:** There is no impact to this goal.

3) **Improve waitlisted patient, living donor, and transplant recipient outcomes:** This proposal collects more granular data on lung dysfunction to help inform future policies for improving lung transplant outcomes.

4) **Promote living donor and transplant recipient safety:** There is no impact to this goal.

5) **Promote the efficient management of the OPTN:** This may increase efficient management of the OPTN in that it should reduce the number of questions the OPTN fields about how to report RAS.

How will the OPTN implement this proposal?

This proposal will require an additional public comment posted in the Federal Register sponsored by the Health Resources and Services Administration (HRSA) to adhere to the Office of Management and
Budget’s guidelines for collecting additional information. This proposal requires programming in UNetSM as it involves modification of TIEDI forms. The 6-month, 1-5 year, and 6+ year TRFs will be modified for both adult and pediatric lung and heart-lung. Changes will also be made to interim forms.

This proposal may require an instructional program and will be monitored for specific needs throughout development and implementation to determine the appropriate education for members.

The OPTN will follow established protocols inform members and educate them on any data collection changes via the OPTN website and in Transplant Pro.

**How will members implement this proposal?**

This proposal will impact lung and heart-lung transplant programs.

**Transplant Hospitals**

Upon implementation, transplant programs will be required to provide new graft function data to the OPTN for all adult and pediatric lung and heart-lung transplant recipients on the relevant TRF. Administrative burden is mitigated by the fact that the new data elements are standard measures obtained during PFT and readily obtainable to both clinical and non-clinical data coordinators in medical records. Minimal staff training may be required.

**Will this proposal require members to submit additional data?**

Yes, additional data collection of FVC and FEF25-75 will be required as a result of this proposal. This data collection effort is justified by the OPTN Principles of Data Collection, which state that “members must provide sufficient data to OPTN to allow it to: a) Develop transplant, donation and allocation policies;… [and] c) determine member-specific performance.”

These data elements are accessible within a patient’s medical record for both clinical and non-clinical coordinators and no interpretation is necessary.

**How will members be evaluated for compliance with this proposal?**

The proposed language will not change the current routine monitoring of OPTN members. Any data entered in UNet may be subject to OPTN review, and members are required to provide documentation as requested.

**How will the sponsoring Committee evaluate whether this proposal was successful post implementation?**

This proposal is designed to capture information about the longitudinal change in lung function in transplant recipients. The data fields were developed to be an improved marker of post-transplant lung function and allow for a broader understanding of graft failure. Summaries will be provided at approximately 6 months after implementation, and then annually thereafter as part of the review of the LAS system for 2-3 years as the Committee sees fit. A summary of the five data elements, including monitoring their use, will be provided for lung transplant recipients following implementation of the TIEDI form changes. As requested, calculations of BOS and RAS will be performed using the collected data. Tabulations of the number of patients with BOS and RAS will also be reported. These will be provided overall and by form type when possible.

---

10 Principles of Data Collection